Prevention and treatment of venous thromboembolism in high risk situations in pregnancy

Fetal and Maternal Medicine Review

Volumn 16, Issue 1, 2005, Pages 51-70

  McLeod, Anne G ^a   Ellis, Cameron ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; TINZAPARIN; VITAMIN D; WARFARIN;

BLEEDING; BLOOD CLOTTING FACTOR 5 DEFICIENCY; CAUSE OF DEATH; CLINICAL TRIAL; DRUG COST; DRUG ELIMINATION; DRUG SAFETY; DRUG TRANSPORT; EMBRYOTOXICITY; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PREGNANCY; HUMAN; INCIDENCE; LUNG EMBOLISM; MATERNAL MORTALITY; MEDICAL DECISION MAKING; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TERATOGENICITY; THROMBOPHILIA; THROMBOSIS PREVENTION; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

EID: 20044381342     PISSN: 09655395     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0965539504001391     Document Type: Review

References (76)

1. Koonin LM, MacKay AP, Berg CJ, Atrash HK, Smith JC. Pregnancy-related mortality surveillance-United States, 1987-1990. MMWR CDC Surveill Summ 1997; 46: 17-36.
2. Drife J Lewis G editors. Why Mothers Die 1997-1999: Fifth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. London: RCOG Press, 2001.
3. Hogberg U, Innala E, Sandstrom A. Maternal mortality in Sweden, 1980-1988. Obstet Gynecol 1994; 84: 240-44.
4. Lindhagen A, Bergqvist A, Bergqvist D, Hallbook T. Late venous function in the leg after deep venous thrombosis occurring in relation to pregnancy. Br J Obstet Gynaecol 1986; 93: 348-52.
5. Eldor A. Thrombophilia, thrombosis and pregnancy. Thromb Haemost 2001; 86: 104-11.
6. Martinelli I, Legnani C, Bucciarelli P, Grandone E, De Stefano V, Mannucci PM. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001; 86: 800-803.
7. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999; 82: 610-19.
8. Eldor A. The use of low-molecular-weight heparin for the management of venous thromboembolism in pregnancy. Eur J Obstet Gynecol Reprod Biol 2002; 104: 3-13.
9. RCOG. Thromboprophylaxis during pregnancy, labour and after vaginal delivery. London: RCOG Press; 2004 January. Guideline No. 37.
10. Kent N, Leduc L, Crane J, Farine D, Hodges S, Reid GJ et al. Prevention and Treatment of Venous Thromboembolism (Vte) in Obstetrics. J Sogc 2000; 22: 736-49.
11. Hague WM, North RA, Gallus AS, Walters BN, Orlikowski C, Burrows RF et al. Anticoagulation in pregnancy and the puerperium. Med J Aust 2001; 175: 258-63.
12. Prophylaxis of Venous Thromboembolism - A national clinical guideline: Scottish Intercollegiate Guidelines Network; 2002 October.
13. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001; 119: 122S-131S.
14. Gherman RB, Goodwin TM, Leung B, Byrne JD, Hethumumi R, Montoro M. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol 1999; 94: 730-34.
15. Lindqvist P, Dahlback B, Marsal K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol 1999; 94: 595-99.
16. McColl MD, Ramsay JE, Tait RC, Walker ID, McCall F, Conkie JA et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78: 1183-88.
17. RCOG. Report of the Royal College of Obstetricians and Gynaecologists (RCOG) Working Party on Prophylaxis Against Thromboembolism in Gynaecology and Obstetrics. London: RCOG Press; 1995.
18. Stein PD, Hull RD, Kayali F, Olson RE, Alshab AK, Meyers FA et al. Venous thromboembolism in pregnancy: 21-year trends. Am J Med 2004; 117: 121-25.
19. Andersen BS, Steffensen FH, Sorensen HT, Nielsen GL, Olsen J. The cumulative incidence of venous thromboembolism during pregnancy and puerperium-an 11 year Danish population-based study of 63,300 pregnancies. Acta Obstet Gynecol Scand 1998; 77: 170-73.
20. Macklon NS, Greer IA. Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. Scott Med J 1996; 41: 83-86.
21. Clark P, Brennand J, Conkie JA, McCall F, Greer IA, Walker ID. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 1166-170.
22. Comp PC, Thurnau GR, Welsh J, Esmon CT. Functional and immunologic protein S levels are decreased during pregnancy. Blood 1986; 68: 881-85.
23. Kjellberg U, Andersson NE, Rosen S, Tengborn L, Hellgren M. APC resistance and other haemostatic variables during pregnancy and puerperium. Thromb Haemost 1999; 81: 527-31.
24. Wright JG, Cooper P, Astedt B, Lecander I, Wilde JT, Preston FE et al. Fibrinolysis during normal human pregnancy: complex inter-relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time. Br J Haematol 1988; 69: 253-58.
25. Bremme K, Ostlund E, Almqvist I, Heinonen K, Blomback M. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium. Obstet Gynecol 1992; 80: 132-37.
26. Macklon NS, Greer IA. The deep venous system in the puerperium: an ultrasound study. Br J Obstet Gynaecol 1997; 104: 198-200.
27. Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52: 176-82.
28. Bonnar J. Blood coagulation and fibrinolysis in human pregnancy. Bibl Anat 1973; 12: 58-63.
29. Ginsberg JS, Brill-Edwards P, Burrows RF, Bona R, Prandoni P, Buller HR et al. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost 1992; 67: 519-20.
30. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353: 1258-265.
31. Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv 1999; 54: 265-71.
32. Macklon NS, Greer IA, Bowman AW. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynaecol 1997; 104: 191-97.
33. Rutherford D, Montoro M, McGhee W, Strong T. Thromboembolic disease associated with pregnancy: an 11 year review. Am J Obstet Gynecol 1991; 164: 286.
34. Ros HS, Lichtenstein P, Bellocco R, Petersson G, Cnattingius S. Pulmonary embolism and stroke in relation to pregnancy: how can high-risk women be identified? Am J Obstet Gynecol 2002; 186: 198-203.
35. Jacobsen AF, Drolsum A, Klow NE, Dahl GF, Qvigstad E, Sandset PM. Deep vein thrombosis after elective cesarean section. Thromb Res 2004; 113: 283-88.
36. Montgomery KD, Geerts WH, Potter HG, Helfet DL. Thromboembolic complications in patients with pelvic trauma. Clin Orthop 1996: (329) 68-87.
37. Brill-Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med 2000; 343: 1439-444.
38. Pabinger I, Grafenhofer H, Kyrle PA, Quehenberger P, Mannhalter C, Lechner K et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood 2002; 100: 1060-62.
39. Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BJ, Hughes GR. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996; 14: 131-36.
40. Ogunyemi D, Cuellar F, Ku W, Arkel Y. Association between inherited thrombophilias, antiphospholipid antibodies, and lipoprotein A levels and venous thromboembolism in pregnancy. Am J Perinatol 2003; 20: 17-24.
41. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002; 41: 924-29.
42. Long AA, Ginsberg JS, Brill-Edwards P, Johnston M, Turner C, Denburg JA et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost 1991; 66: 520-24.
43. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682-98.
44. Ginsberg JS, Brill-Edwards P, Johnston M, Denburg JA, Andrew M, Burrows RF et al. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study. Blood 1992; 80: 975-80.
45. Kujovich JL. Hormones and pregnancy: thromboembolic risks for women. Br J Haematol 2004; 126: 443-54.
46. Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210-13.
47. Dizon-Townson DS, Nelson LM, Jang H, Varner MW, Ward K. The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis. Am J Obstet Gynecol 1997; 176: 883-86.
48. Bokarewa MI, Bremme K, Blomback M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996; 92: 473-78.
49. Hallak M, Senderowicz J, Cassel A, Shapira C, Aghai E, Auslender R et al. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol 1997; 176: 889-93.
50. Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342: 374-80.
51. Grandone E, Margaglione M, Colaizzo D, D'Andrea G, Cappucci G, Brancaccio V et al. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol 1998; 179: 1324-328.
52. Gerhardt A, Scharf RE, Zotz RB. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. Thromb Haemost 2003; 90: 77-85.
53. Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci PM. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 2002; 87: 791-95.
54. Meglic L, Stegnar M, Milanez T, Bozic M, Peterlin B, Peternel P et al. Factor V Leiden, prothrombin 20210G → A, methylenetetrahydrofolate reductase 677C → T and plasminogen activator inhibitor 4G/5G polymorphism in women with pregnancy-related venous thromboembolism. Eur J Obstet Gynecol Reprod Biol 2003; 111: 157-63.
55. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338: 1793-797.
56. Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 1990; 63: 319-20.
57. Lindqvist PG, Kublikas M, Dahlback B. Individual risk assessment of thrombosis in pregnancy. Acta Obstet Gynecol Scand 2002; 81: 412-16.
58. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295-302.
59. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 1994; 343: 619-29.
60. Kozer E, Nikfar S, Costei A, Boskovic R, Nulman I, Koren G. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol 2002; 187: 1623-630.
61. Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81: 668-72.
62. Ginsberg JS, Hirsh J, Turner DC, Levine MN, Burrows R. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989; 61: 197-203.
63. Ginsberg JS, Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R. Heparin therapy during pregnancy. Risks to the fetus and mother. Arch Intern Med 1989; 149: 2233-236.
64. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-335.
65. Myers B, Westby J, Strong J. Prophylactic use of danaparoid in high-risk pregnancy with heparin-induced thrombocytopaenia-positive skin reaction. Blood Coagul Fibrinolysis 2003; 14: 485-87.
66. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71: 7-11.
67. Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002; 87: 182-86.
68. Dahlman T, Lindvall N, Hellgren M. Osteopenia in pregnancy during long-term heparin treatment: a radiological study post partum. Br J Obstet Gynaecol 1990; 97: 221-28.
69. von Mandach U, Aebersold F, Huch R, Huch A. Short-term low-dose heparin plus bedrest impairs bone metabolism in pregnant women. Eur J Obstet Gynecol Reprod Biol 2003; 106: 25-30.
70. Haram K, Thordarson H, Hervig T. Calcium homeostasis in pregnancy and lactation. Acta Obstet Gynecol Scand 1993; 72: 509-13.
71. Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999; 181: 1113-117.
72. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S-94S.
73. de Valk HW, Banga JD, Wester JW, Brouwer CB, van Hessen MW, Meuwissen OJ et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med 1995; 123: 1-9.
74. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160: 181-88.
75. Ginsberg JS, Bates SM. Management of venous thromboembolism during pregnancy. J Thromb Haemost 2003; 1: 1435-442.
76. Brandjes DP, Buller HR, Heijboer H, Huisman MV, de Rijk M, Jagt H et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349: 759-62.